Publications by authors named "G Perez-Pastor"
Background: Following the pivotal phase II trial BOLT, the Hedgehog (Hh) inhibitor sonidegib was approved in the EU to treat locally advanced basal cell carcinoma (laBCC) in patients not amenable to surgery or radiotherapy. We report safety data from the interim analysis of the real-world NISSO study.
Methods: NISSO is an ongoing non-interventional, multinational, post-authorization safety study (NCT04066504).
Article Synopsis
- Severe recurrent aphthous stomatitis (RAS) significantly affects quality of life, and currently, no approved systemic treatments exist, prompting the exploration of roflumilast, a phosphodiesterase-4 inhibitor.
- In a study involving 22 RAS patients across five Spanish centers, roflumilast treatment resulted in substantial improvements, including an 88% reduction in flare-ups and a 94% decrease in oral ulcers over 12 weeks.
- Despite some adverse effects (mainly headache and gastrointestinal issues), roflumilast was generally well tolerated, showing promise as an effective and safe treatment option for RAS.
Background: Mucocutaneous Behçet disease often presents a therapeutic challenge. Roflumilast has shown promise in the treatment of other inflammatory dermatological conditions.
Objectives: The objective of this study was to evaluate the characteristics, effectiveness and safety of roflumilast in the treatment of Behçet disease-associated aphthosis in routine clinical practice.